Search Videos and More
News
Computer Platform Helps Match Patients With Cancer to Trials of Targeted Therapy
MatchMiner shortens time to identify appropriate precision medicine trials for individual patients
News
Study Finds Individuals With Inflammatory Breast Cancer at Higher Risk of Cancer Spread to the Brain
New research from Dana-Farber Cancer Institute indicates that among individuals with breast cancer, those with a rare subtype called inflammatory breast cancer face a higher risk that their cancer will spread, or metastasize, to the brain.
News
Dana-Farber’s Kornelia Polyak Elected to the National Academy of Medicine
Kornelia Polyak, M.D., Ph.D., professor of medicine, medical oncology, Dana-Farber Cancer Institute has been elected to the prestigious National Academy of Medicine.
News
Kornelia Polyak Wins Prestigious American Cancer Society Award
Kornelia Polyak, MD, PhD, a breast cancer researcher at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School is the recipient of the American Cancer Society’s prestigious Research Professor Award.
Document
Treatment Guidelines: Adjuvant Olaparib for BRCA1/2 Variant Carriers
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on May 6, May 20, June 1, and August 5, 2022 to discuss recommendations for the use of adjuvant olaparib for high-risk, breast cancer in BRCA1/2 carriers.Symposium Highlights 75 Years of Dana-Farber Science
Document
Treatment Guidelines: Reflex Testing of OncotypeDX for Early Stage Breast Cancer
The Breast Oncology Center held multidisciplinary meetings to discuss recommendations for updated criteria for reflex testing of OncotypeDX in patients with resected, hormone receptor positive, HER-2 negative, early breast cancer.
News
Advancing New Treatments for Uncommon Cancer Subtypes
The biology of rare cancers is poorly understood in part because the tumors are uncommon, which makes them challenging to study. Clinical trials examining rare cancers are difficult.
Symposium
ESMO Congress 2022 Research Highlights
In the following videos, faculty from Dana-Farber Cancer Institute review research highlights from the ESMO Congress 2022 held in Paris, France, September 9-13, 2022.
News
For Older Patients with Blood Cancer Taking Multiple Medications, New Tool Links Use of Certain Medications to Risk of Frailty
A new tool developed by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital outperforms conventional methods for predicting whether certain medications are likely to lead to frailty in older patients with blood cancers who are taking multiple medications, a study being published online today indicates.
News
In Memoriam: Arthur T. Skarin, MD, Physician-Scientist Instrumental in Building Dana-Farber’s Adult Oncology Program
The Dana-Farber community mourns the passing of Arthur T. Skarin, MD, of Needham, Massachusetts.
News
Online Testing Tool Identifies People Likely to Benefit from Genetic Testing for Inherited Risk for Certain Cancers
An online tool developed by researchers and physicians at Dana-Farber Cancer Institute can accurately and rapidly identify people who should undergo testing for inherited genetic changes that raise the risk of developing certain cancers, a new study shows.